CAR-T Cell Therapy (Approved 2017): Chimeric Antigen Receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment that engineers a patient’s own immune cells to target tumors. T cells are extracted, genetically modified to express receptors that recognize cancer-specific antigens, then reinfused. Approved for certain leukemias and lymphomas, CAR-T has achieved remission in patients unresponsive to conventional treatments. While challenges like high cost, cytokine release syndrome, and limited solid tumor efficacy remain, CAR-T exemplifies the power of personalized immunotherapy. It represents a shift from broad chemotherapy to targeted, living drugs. Ongoing research aims to improve safety, reduce costs, and expand applications, making it a cornerstone of next-generation oncology.
Add Comment + Vote ( 1 )...
There are currently no comments !